Login to Your Account

New CEO Accelerating Virttu's Oncolytic Virus Drug Seprehvir

By Nuala Moran
Staff Writer

Wednesday, September 19, 2012
LONDON – Virttu Biologics Ltd. hired biotech veteran Steven Powell as CEO, with a brief to reshape strategy and turbo-charge efforts to commercialize oncolytic virus Seprehvir, a broad-spectrum product that has yet to reach the advanced stages of clinical development despite having been tested in more than 75 patients, in a number of solid tumors.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription